| pubmed-article:11281646 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11281646 | lifeskim:mentions | umls-concept:C0205147 | lld:lifeskim |
| pubmed-article:11281646 | lifeskim:mentions | umls-concept:C0597357 | lld:lifeskim |
| pubmed-article:11281646 | lifeskim:mentions | umls-concept:C0041485 | lld:lifeskim |
| pubmed-article:11281646 | lifeskim:mentions | umls-concept:C0205289 | lld:lifeskim |
| pubmed-article:11281646 | lifeskim:mentions | umls-concept:C1879547 | lld:lifeskim |
| pubmed-article:11281646 | lifeskim:mentions | umls-concept:C1514873 | lld:lifeskim |
| pubmed-article:11281646 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:11281646 | pubmed:dateCreated | 2001-4-3 | lld:pubmed |
| pubmed-article:11281646 | pubmed:abstractText | Mutating tyrosines 579 and 581 of the beta platelet-derived growth factor receptor (betaPDGFR) tyrosine kinase to phenylalanines (the F2 mutation) impair activation of the receptor in response to ligand, but mutation of the analogous tyrosines in the alphaPDGFR has no effect on ligand-dependent receptor activation. We have found that the F2 mutation has only a modest effect on ligand-dependent activation of a chimeric PDGFR composed of the extracellular and transmembrane domains of the alphaPDGFR and the cytoplasmic domain of the betaPDGFR by three measures: (1) the ability to phosphorylate endogenous and exogenous protein substrates in vitro, (2) phosphorylation of tyrosine 857, and (3) binding of the effector proteins PLCgamma, RasGAP, and SHP-2. Conversely, the F2 mutation substantially impairs ligand-dependent activation of chimeric PDGFRs that consist of either the extracellular domain alone or the extracellular and transmembrane domains of the betaPDGFR and all remaining sequence from the alphaPDGFR by two measures: (1) phosphorylation of endogenous protein substrates in vitro and (2) binding of PLCgamma and SHP-2. Our results indicate that the requirement of tyrosines 579 and 581 for maximal activation of the betaPDGFR in response to ligand is primarily determined by noncytoplasmic regions of the receptor. | lld:pubmed |
| pubmed-article:11281646 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11281646 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11281646 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11281646 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11281646 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11281646 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11281646 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11281646 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11281646 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11281646 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11281646 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:11281646 | pubmed:issn | 0014-4827 | lld:pubmed |
| pubmed-article:11281646 | pubmed:author | pubmed-author:BernardAA | lld:pubmed |
| pubmed-article:11281646 | pubmed:author | pubmed-author:KazlauskasAA | lld:pubmed |
| pubmed-article:11281646 | pubmed:author | pubmed-author:NickasM EME | lld:pubmed |
| pubmed-article:11281646 | pubmed:copyrightInfo | Copyright 2001 Academic Press. | lld:pubmed |
| pubmed-article:11281646 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11281646 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:11281646 | pubmed:volume | 265 | lld:pubmed |
| pubmed-article:11281646 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11281646 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11281646 | pubmed:pagination | 80-9 | lld:pubmed |
| pubmed-article:11281646 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:11281646 | pubmed:meshHeading | pubmed-meshheading:11281646... | lld:pubmed |
| pubmed-article:11281646 | pubmed:meshHeading | pubmed-meshheading:11281646... | lld:pubmed |
| pubmed-article:11281646 | pubmed:meshHeading | pubmed-meshheading:11281646... | lld:pubmed |
| pubmed-article:11281646 | pubmed:meshHeading | pubmed-meshheading:11281646... | lld:pubmed |
| pubmed-article:11281646 | pubmed:meshHeading | pubmed-meshheading:11281646... | lld:pubmed |
| pubmed-article:11281646 | pubmed:meshHeading | pubmed-meshheading:11281646... | lld:pubmed |
| pubmed-article:11281646 | pubmed:meshHeading | pubmed-meshheading:11281646... | lld:pubmed |
| pubmed-article:11281646 | pubmed:meshHeading | pubmed-meshheading:11281646... | lld:pubmed |
| pubmed-article:11281646 | pubmed:meshHeading | pubmed-meshheading:11281646... | lld:pubmed |
| pubmed-article:11281646 | pubmed:meshHeading | pubmed-meshheading:11281646... | lld:pubmed |
| pubmed-article:11281646 | pubmed:meshHeading | pubmed-meshheading:11281646... | lld:pubmed |
| pubmed-article:11281646 | pubmed:meshHeading | pubmed-meshheading:11281646... | lld:pubmed |
| pubmed-article:11281646 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11281646 | pubmed:articleTitle | The requirement of tyrosines 579 and 581 for maximal ligand-dependent activation of the betaPDGFR is influenced by noncytoplasmic regions of the receptor. | lld:pubmed |
| pubmed-article:11281646 | pubmed:affiliation | The Schepens Eye Research Institute, Harvard Medical School, Boston, Massachusetts 02114, USA. | lld:pubmed |
| pubmed-article:11281646 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11281646 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
